Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis

Trial Profile

Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Cardiovascular disorders; Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RORA
  • Most Recent Events

    • 11 Jun 2008 Results presented at the 2008 Annual European Congress of Rheumatology.
    • 06 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top